Art. -Nr.: HY-100514

GSK484 hydrochloride

54 Cited Publications

Kundenbewertung

Based on 54 publication(s) in Google Scholar

GSK484 hydrochloride is a selective and reversible peptidylarginine deiminase 4 (PAD4) inhibitor. GSK484 hydrochloride demonstrates high affinity binding to PAD4 with IC₅₀s of 50 nM in the absence of Calcium. In the presence of 2 mM Calcium, notably lower potency (250 nM) is observed.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.48%
CAS. Nr.: 1652591-81-5
Formel: C₂₇H₃₂ClN₅O₃
Molecular Weight:510.03

Speicherung:

4°C, stored under nitrogen, away from moisture

* In solvent : -80°C, 1 year; -20°C, 6 months (stored under nitrogen, away from moisture)

GSK484 hydrochloride Chemical Structure

CAS. Nr.: 1652591-81-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (54)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 50 nM (PAD4, in the absence of Calcium), 250 nM (PAD4, in the presence of 2 mM Calcium)^[1]

In Vitro

GSK484 demonstrates high affinity binding to the low-calcium form of PAD4 with IC₅₀s of 50 nM and 250 nM in the absence of Calcium (0 mM) and Calcium (2 mM), respectively. GSK484 also inhibits PAD4 citrullination (at 0.2 mM Calcium) of benzoyl-arginine ethyl ester (BAEE) substrate in a concentration-dependent manner, as detected using an NH₃ release assay^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

To address whether PAD4 inhibition can suppress cancer-associated kidney injury, MMTV-PyMT mice are treated with the PAD4 inhibitor GSK484 at 4 mg/kg daily for one week. This dose suppress the elevated number of neutrophils undergoing NETosis in peripheral blood in mice with cancer. In parallel, the total protein level in urine from MMTV-PyMT mice is significantly reduced compared with untreated tumor-bearing mice, further supporting an improved functional status of the kidneys after GSK484 treatment. Administration of GSK484 at a dose of 4 mg/kg daily during one week reverts signs of kidney dysfunction in tumor-bearing mice to the same extent as DNase I treatment, without any detectable signs of toxicity^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 1652591-81-5
Appearance Solid
Molecular Weight 510.03
Formel C₂₇H₃₂ClN₅O₃
Color Off-white to light yellow
SMILES

O=C(N1C[C@H](N)[C@H](O)CC1)C2=CC(OC)=C3C(N=C(C(N4CC5CC5)=CC6=C4C=CC=C6)N3C)=C2.[H]Cl
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, stored under nitrogen, away from moisture

* In solvent : -80°C, 1 year; -20°C, 6 months (stored under nitrogen, away from moisture)

Publications (54)

All In Vivo Efficacy Study

Sort by:

Journal Impact Factor

Cancer Cell

DNASE1L3-expressing dendritic cells promote CD8+ T cell function and anti-PD-(L)1 therapy efficacy by degrading neutrophil extracellular traps. [Abstract]

2025 Sep 8;43(9):1758-1775.e8. PMID: 40816293

GSK484 hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2025 Sep 8;43(9):1758-1775.e8. [Abstract]

Schema for GSK484 treatment protocol and summary tumor growth curves of MC38 in Dnase1l3fl/fl and Dnase1l3cko mice (n = 7).
Cancer Cell

Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation. [Abstract]

2021 Mar 8;39(3):423-437.e7. PMID: 33450198

GSK484 hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2021 Mar 8;39(3):423-437.e7. [Abstract]

Mice were treated with GSK484 (20 mg/kg, i.p. daily shots for 20 days from day 7, and then maintenance shots every two days) following orthotopic injection of AT3 cells. Shown are BLI quantification of primary tumor growth at day 19.

GSK484 hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2021 Mar 8;39(3):423-437.e7. [Abstract]

Mice were treated with GSK484 (20 mg/kg, i.p. daily shots for 20 days from day 7, and then maintenance shots every two days) following orthotopic injection of AT3 cells. Shown are BLI quantification of lung metastasis at week 5.

GSK484 hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2021 Mar 8;39(3):423-437.e7. [Abstract]

Mice were treated with GSK484 (20 mg/kg, i.p. daily shots for 20 days from day 7, and then maintenance shots every two days) following orthotopic injection of AT3 cells. Shown are pulmonary surface nodules at week 5.

GSK484 hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2021 Mar 8;39(3):423-437.e7. [Abstract]

Mice were treated with GSK484 (20 mg/kg, i.p. daily shots for 20 days from day 7, and then maintenance shots every two days) following orthotopic injection of AT3 cells. Shown are NET formation in lung metastases.
Immunity

The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer. [Abstract]

2023 Dec 12;56(12):2755-2772.e8. PMID: 38039967
Immunity

CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity. [Abstract]

2020 May 19;52(5):856-871.e8. PMID: 32289253
Cancer Commun (Lond)

2025 Dec 15.
Cell Mol Immunol

Neutrophil ALDH2 is a new therapeutic target for the effective treatment of sepsis-induced ARDS. [Abstract]

2024 May;21(5):510-526. PMID: 38472357
Adv Funct Mater

2025 Aug 3.
Nat Commun

Oxidized mitochondrial DNA induces gasdermin D oligomerization in systemic lupus erythematosus. [Abstract]

2023 Feb 16;14(1):872. PMID: 36797275
J Adv Res

PAD4-mediated citrullination of IGF2BP2 stabilizes MCM mRNAs to drive intrahepatic cholangiocarcinoma progression. [Abstract]

2026 Jun 5:S2090-1232(26)00460-1. PMID: 42250722
Mol Cell

Targeted citrullination enables p53 binding to non-canonical sites. [Abstract]

2025 Oct 2;85(19):3588-3604.e11. PMID: 41043392
Adv Sci (Weinh)

Bifidobacterium Breve Yang08 Alleviates Atopic Dermatitis By Enriching Akkermansia Muciniphila and Inhibiting Neutrophil Extracellular Traps Formation In Mice. [Abstract]

2026 Apr;13(20):e18588. PMID: 41655253
Adv Sci (Weinh)

Succinate Dehydrogenase Subunit A (SDHA) Mediated Microglia Extracellular Traps Formation Participating in Cerebral Ischemic Reperfusion Injury. [Abstract]

2025 Aug 20:e11873. PMID: 40832885
Adv Sci (Weinh)

The CXCL10-CXCR3 Axis Induces Tumor-Associated Neutrophils to Interfere with CTLs-Mediated Antitumor Activity in EBV-Associated Epithelial Cancers. [Abstract]

2025 Jul 21:e00950. PMID: 40686457
Adv Sci (Weinh)

NETs-CD44-IL-17A Feedback Loop Drives Th17-Mediated Inflammation in Behçet's Uveitis. [Abstract]

2025 Apr;12(16):e2411524. PMID: 40013981
Adv Sci (Weinh)

ACSL1 Aggravates Thromboinflammation by LPC/LPA Metabolic Axis in Hyperlipidemia Associated Myocardial Ischemia-Reperfusion Injury. [Abstract]

2025 Jan 23:e2406359. PMID: 39853712
Adv Sci (Weinh)

Neutrophil-Mediated Tumor-Targeting Delivery System of Oncolytic Bacteria Combined with ICB for Melanoma Lung Metastasis Therapy. [Abstract]

2023 Oct;10(29):e2301835. PMID: 37565362
Cell Death Differ

EGFR orchestrates neutrophil activation and NETosis via CEBPβ-dependent PGLYRP1 induction. [Abstract]

2026 Jan 15. PMID: 41540251
Research (Wash D C)

Neuromodulation and Copper Chelation Reverse Sleep Fragmentation-Aggravated Myocardial Ischemia-Reperfusion Injury by Targeting NET-Induced Endothelial Cuproptosis. [Abstract]

2026 May 8:9:1266. PMID: 42109881
Pharmacol Res

Targeting P2RX1 alleviates renal ischemia/reperfusion injury by preserving mitochondrial dynamics. [Abstract]

2021 Aug:170:105712. PMID: 34091010
J Immunother Cancer

Tumor cell-released autophagosomes (TRAPs) induce PD-L1-decorated NETs that suppress T-cell function to promote breast cancer pulmonary metastasis. [Abstract]

2024 Jun 26;12(6):e009082. PMID: 38926151
Phytomedicine

Shegan Mahuang Decoction ameliorates pulmonary fibrosis progression by inhibiting CCL3-mediated NETosis. [Abstract]

2026 Aug:158:158386. PMID: 42275874
Diabetologia

Intestinal neutrophil extracellular traps promote gut barrier damage exacerbating endotoxaemia, systemic inflammation and progression of diabetic retinopathy in type 2 diabetes. [Abstract]

2025 Apr;68(4):866-889. PMID: 39875729
J Tissue Eng

Formation of neutrophil extracellular traps in the early stages exacerbate the healing process by regulating macrophage polarization in Achilles tendon-bone injury. [Abstract]

2025 Aug 19:16:20417314251348038. PMID: 40843411
Apoptosis

Neutrophil extracellular traps mediate TLR9/Merlin axis to resist ferroptosis and promote triple negative breast cancer progression. [Abstract]

2023 Oct;28(9-10):1484-1495. PMID: 37368176
Cell Rep

Inappropriate use of antibiotics exacerbates inflammation through OMV-induced pyroptosis in MDR Klebsiella pneumoniae infection. [Abstract]

2021 Sep 21;36(12):109750. PMID: 34551309
Br J Pharmacol

Neutrophil extracellular traps drive tubulointerstitial fibrosis via the coiled-coil domain-containing protein 25 (CCDC25)-Yes-associated protein 1 (YAP1) axis-mediated autophagy regulation. [Abstract]

2026 May 27. PMID: 42204873
Front Immunol

Reduced Neutrophil Extracellular Trap Formation During Ischemia Reperfusion Injury in C3 KO Mice: C3 Requirement for NETs Release. [Abstract]

2022 Feb 16:13:781273. PMID: 35250972
JCI Insight

HMGB1-mediated formation of IL-33-abundant NETs drives lung-to-kidney injury in severe pneumonia-associated acute kidney injury. [Abstract]

2026 May 22;11(10):e191979. PMID: 42171612
JCI Insight

The CHI3L1-neutrophil axis drives immune suppression and breast cancer metastatic dissemination. [Abstract]

2026 Feb 3:e199307. PMID: 41632530
OncoImmunology

Neutrophil extracellular traps induce tumor metastasis through dual effects on cancer and endothelial cells. [Abstract]

2022 Mar 16;11(1):2052418. PMID: 35309732
Int Immunopharmacol

The natural compound PEITC ameliorates imiquimod-induced psoriasis in mice by suppressing neutrophil extracellular traps formation. [Abstract]

2025 May 24:159:114939. PMID: 40414074
Int Immunopharmacol

Berberine regulates PADI4-related macrophage function to prevent lung cancer. [Abstract]

2022 Sep:110:108965. PMID: 35764017
Int Immunopharmacol

Protectin D1 decreases pancreatitis severity in mice by inhibiting neutrophil extracellular trap formation. [Abstract]

2021 May:94:107486. PMID: 33639566
Front Cell Infect Microbiol

Veillonella parvula outer membrane vesicles increase ICAM-1+ neutrophils exhibiting elevated NET formation via ROS-PAD4 signaling. [Abstract]

2025 Jun 11:15:1540634. PMID: 40568695
Mucosal Immunol

PAD4 inhibition impacts immune responses in SARS-CoV-2 infection. [Abstract]

2025 Apr 19:S1933-0219(25)00044-3. PMID: 40258416
J Thromb Haemost

NETs induce persistent lung tissue damage via thromboinflammation without altering virus resolution in a mouse coronavirus model. [Abstract]

2024 Jan;22(1):188-198. PMID: 37748582
Rheumatology (Oxford)

Autophagy inhibitors block pathogenic NET release in immune-mediated inflammatory disease without impairing host defence. [Abstract]

2025 Aug 13:keaf437. PMID: 40802538
Transl Stroke Res

Neutrophil Extracellular Traps Induce Brain Edema Around Intracerebral Hematoma via ERK-Mediated Regulation of MMP9 and AQP4. [Abstract]

2024 Dec 28. PMID: 39733198
FEBS J

Neutrophil extracellular traps boost laser-induced mouse choroidal neovascularization through the activation of the choroidal endothelial cell TLR4/HIF-1α pathway. [Abstract]

2023 Nov;290(22):5395-5410. PMID: 37552110
Transl Stroke Res

Neutrophil Extracellular Traps may be a Potential Target for Treating Early Brain Injury in Subarachnoid Hemorrhage. [Abstract]

2022 Feb;13(1):112-131. PMID: 33852132
Parasit Vectors

Pentatrichomonas hominis induces extracellular traps formation of macrophages via the TLR2/NADPH/PAD4 pathway. [Abstract]

2025 Jul 1;18(1):248. PMID: 40598534
Kidney Dis (Basel)

Clinical and Experimental Insights into the Role of NETosis in IgA Nephropathy Pathogenesis. [Abstract]

2025 May 9;11(1):450-468. PMID: 40606676
Fitoterapia

Er Miao San and its main components phellodendrine and atractylenolide-I exert anti-rheumatoid arthritis effects by inhibiting PAD4 and thereby reducing the formation of NETs. [Abstract]

2025 Sep:185:106771. PMID: 40738459
Vet Microbiol

The PERK-eIF2α branch activates the NLRP3 inflammasome through the NF-κB signaling pathway to suppress NDV replication. [Abstract]

2026 May:316:110968. PMID: 41793984
Physiol Res

Targeting the Toll-Like Receptor 4 Ameliorates Heart Failure in Aged Mice by Inhibiting the Formation of Neutrophil Extracellular Traps. [Abstract]

2026 Mar 11;75(1):29-43. PMID: 41811699
STAR Protoc

Protocol for identification of protein citrullination by immunoprecipitation followed by mass spectrometry. [Abstract]

2026 Jan 12;7(1):104326. PMID: 41528850
Hlife

2026 Mar 18.
bioRxiv

2025 Sep 5.
bioRxiv

APOE Protects Against Severe Infection with Mycobacterium tuberculosis by Restraining Production of Neutrophil Extracellular Traps. [Abstract]

2024 Oct 4:2024.10.04.616580. PMID: 39605723
bioRxiv

2024 July 01.
Sci Tradit Chin Med

2023 Sep 20.
Research Square Preprint

2023 May 11.
bioRxiv

2023 Apr 3.
Aging Cell

Kindlin-3 in platelets and myeloid cells differentially regulates deep vein thrombosis in mice. [Abstract]

2019 Aug 31;11(17):6951-6959. PMID: 31477636

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 100 mg/mL (196.07 mM; Need ultrasonic)

DMSO : 100 mg/mL (196.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9607 mL

9.8033 mL

19.6067 mL

5 mM

0.3921 mL

1.9607 mL

3.9213 mL

10 mM

0.1961 mL

0.9803 mL

1.9607 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Saline

Solubility: 100 mg/mL (196.07 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Protokoll

Kinase Assay^[1]

PAD4 is serially diluted in the presence of 10 nM GSK215 in assay buffer (100 mM HEPES, pH 8, 50 mM NaCl, 5% glycerol, 1 mM CHAPS, 1 mM DTT) at varying concentrations of calcium (0, 0.2, 2 and 10 mM). Following incubation for 50 min, apparent K_ds for each calcium concentration are determined using a single site saturation curve. For IC₅₀ determination, test compounds (e.g., GSK484) are serially diluted in DMSO (1% final assay concentration) and tested at the same range of calcium concentrations in the presence of PAD4 (at the calculated K_d for each calcium condition) and 10 nM GSK215 in the same assay buffer and volume. Reactions are incubated for 50 min after which IC₅₀ values are calculated using a four-parameter logistic equation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[1]

HEK293 cells stably expressing N-terminal FLAG-tagged PAD1, PAD2, PAD3 or PAD4 are engineered by retroviral transduction. Cells are grown in 15 cm diameter plates to subconfluency in DMEM supplemented with 10% Foetal Bovine Serum, harvested by centrifugation and washed once in PBS/2 mM EGTA. Cells are lysed in 50 mM Tris-Cl, pH 7.4, 1.5 mM MgCl₂, 5% glycerol, 150 mM NaCl, 25 mM NaF, 1 mM Na₃VO₄, 0.4% NP40, 1 mM DTT with protease inhibitors. Lysates are pre-incubated for 20 min at 4°C with DMSO alone (2%), 100 µM of GSK199, GSK484, GSK106 or 200 µM Cl-amidine. Citrullination reactions are performed for 30 min at 37°C in the presence of 2 mM calcium. Extracts are loaded on to gels, proteins separated by SDS-PAGE and transferred to PVDF membranes. Citrullinated proteins are then chemically modified and detected using anti-modified citrulline antibody. FLAG-PAD constructs are detected using anti-FLAG antibody^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice^[2]
The study includes two transgenic mouse models, the MMTV-PyMT mouse model for mammary carcinoma (FVB/n background) and the RIP1-Tag2 mouse model for pancreatic neuroendocrine carcinoma (C57BL/6 background). Mice are treated daily by intra-peritoneal injections of the PAD4 inhibitor GSK484 (4 mg/kg). GSK484 is dissolved in 99.9% ethanol at a concentration of 25 mg/mL to generate a stock solution and further diluted 1:50 in 0.9% NaCl shortly before injection of 200 μL/mouse^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Lewis HD, et al. Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat Chem Biol. 2015 Mar;11(3):189-91. [Content Brief]

[2]. Cedervall J, et al. Pharmacological targeting of peptidylarginine deiminase 4 prevents cancer-associated kidney injury in mice. Oncoimmunology. 2017 Apr 20;6(8):e1320009. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	1.9607 mL	9.8033 mL	19.6067 mL	49.0167 mL
	5 mM	0.3921 mL	1.9607 mL	3.9213 mL	9.8033 mL
	10 mM	0.1961 mL	0.9803 mL	1.9607 mL	4.9017 mL
	15 mM	0.1307 mL	0.6536 mL	1.3071 mL	3.2678 mL
	20 mM	0.0980 mL	0.4902 mL	0.9803 mL	2.4508 mL
	25 mM	0.0784 mL	0.3921 mL	0.7843 mL	1.9607 mL
	30 mM	0.0654 mL	0.3268 mL	0.6536 mL	1.6339 mL
	40 mM	0.0490 mL	0.2451 mL	0.4902 mL	1.2254 mL
	50 mM	0.0392 mL	0.1961 mL	0.3921 mL	0.9803 mL
	60 mM	0.0327 mL	0.1634 mL	0.3268 mL	0.8169 mL
	80 mM	0.0245 mL	0.1225 mL	0.2451 mL	0.6127 mL
	100 mM	0.0196 mL	0.0980 mL	0.1961 mL	0.4902 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

GSK484 hydrochloride

54 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

GSK484 hydrochloride

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Anti-Cardiovascular Disease Compound Library

Endocrinology Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) GSK484 hydrochloride

Biologische Aktivität

Chemical Information

Publications (54)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

GSK484 hydrochloride

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Anti-Cardiovascular Disease Compound Library

Endocrinology Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) GSK484 hydrochloride

Biologische Aktivität

Chemical Information

Publications (54)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

GSK484 hydrochloride Related Classifications

HY-100514 Related Classifications